No Data
No Data
Yabao Pharmaceutical Group (600351.SH) reported a net income of 0.107 billion yuan in the first quarter, a decrease of 4.45% year-on-year.
Gelonghui, April 26丨Yabao Pharmaceutical Group (600351.SH) released its quarterly report, achieving a total operating income of 0.615 billion yuan in the first quarter of 2025, a year-on-year decrease of 20.32%; net income attributable to shareholders of the parent company was 0.107 billion yuan, a year-on-year decrease of 4.45%; and the basic EPS was 0.1522 yuan.
Yabao Pharmaceutical Group Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Yabao Pharmaceutical Group Co., Ltd.
Yabao Pharmaceutical Group Co., Ltd. Report for the first quarter of 2024
Express News | Yabao Pharmaceutical Group: In 2024, the net income increased by 21.60% year-on-year.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.